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Abstract
Background—Psychiatric comorbidity is common among individuals with addictive disorders, 
with patients frequently suffering from anxiety disorders. While the genetic architecture of 
comorbid addictive and anxiety disorders remains unclear, elucidating the genes involved could 
provide important insights into the underlying etiology.
Methods—Here we examine a sample of 1284 Mexican-Americans from randomly selected 
extended pedigrees. Variance decomposition methods were used to examine the role of genetics in 
addiction phenotypes (lifetime history of alcohol dependence, drug dependence or chronic 
smoking) and various forms of clinically relevant anxiety. Genome-wide univariate and bivariate 
linkage scans were conducted to localize the chromosomal regions influencing these traits.
Results—Addiction phenotypes and anxiety were shown to be heritable and univariate genome-
wide linkage scans revealed significant quantitative trait loci for drug dependence (14q13.2–q21.2, 
LOD = 3.322) and a broad anxiety phenotype (12q24.32–q24.33, LOD = 2.918). Significant 
positive genetic correlations were observed between anxiety and each of the addiction subtypes 
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(ρg = 0.550–0.655) and further investigation with bivariate linkage analyses identified significant 
pleiotropic signals for alcohol dependence-anxiety (9q33.1–q33.2, LOD = 3.054) and drug 
dependence-anxiety (18p11.23–p11.22, LOD = 3.425).
Conclusions—This study confirms the shared genetic underpinnings of addiction and anxiety 
and identifies genomic loci involved in the etiology of these comorbid disorders. The linkage 
signal for anxiety on 12q24 spans the location of TMEM132D, an emerging gene of interest from 
previous GWAS of anxiety traits, whilst the bivariate linkage signal identified for anxiety-alcohol 
on 9q33 peak coincides with a region where rare CNVs have been associated with psychiatric 
disorders. Other signals identified implicate novel regions of the genome in addiction genetics.
Keywords
Addiction; Anxiety; Comorbidity; Pleiotropy
1. Introduction
Amongst individuals addicted to licit and illicit substances, the prevalence of comorbid 
psychiatric illnesses is high. In particular, epidemiological evidence for the pattern of 
comorbidity between addiction and anxiety is well established [1]; in addicted populations, 
there is a significant increase in the risk for anxiety disorders, even when covarying for 
demographic characteristics and other psychiatric diagnoses [2,3]. For example, among 
individuals with alcohol dependence the risk of panic disorder and posttraumatic stress 
disorder are doubled and that for generalized anxiety disorder is four times the population 
risk [4]. As the severity of substance misuse increases, so does the observed rate of anxiety 
comorbidity [2,5]. Psychiatric comorbidities are also associated with poorer outcomes 
among individuals with addictive disorders, including more severe symptomatology, greater 
social and functional impairments and increased suicide risk [6]. The lifetime prevalence of 
anxiety disorders and substance disorders are estimated at 18.1% and 14.6%, respectively 
[7], making the impact of this elevated risk substantial. However, the directionality of these 
effects is not clear. Increased comorbidity could be conceptualized as addiction increasing 
the likelihood of anxiety (due to drug use or withdrawal [8]), anxiety increasing the 
likelihood of addiction (to self-medicate symptoms [9]), or a third factor increasing the risk 
of both addiction and anxiety [5]. Disentangling these influences is highly complex, but as a 
potential starting point to unpick this relationship, twin and family studies focusing on 
alcohol disorders suggest that there may be a shared genetic etiology influencing liability to 
both addiction and anxiety [5,10,11].
Genetics play an important role in addiction disorders [12]. Heritability estimate for 
addiction to specific drugs are well established [13]. Furthermore, twin and family studies 
indicate that in addition to substance-specific genetic influences, there are common genetic 
factors acting across addiction phenotypes [14–16]. These findings suggest that genetic 
liability to addictive disorders arises from an increased propensity to addiction in general, 
combined with influences that are specific to that particular drug. Similarly, anxiety 
disorders are interlinked with one another, with high comorbidity rates (one study estimates 
76% of anxiety cases have a experienced at least one other anxiety or depressive disorder 
[17]). We know that anxiety disorders are heritable [18,19], and as with addiction 
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phenotypes, multivariate analyses exploring the genetic relationship between the different 
anxiety disorders have been undertaken. Results indicate an important role for common 
genetic influences acting across anxiety subtypes in addition to subtype-specific genetic 
influences [20–22]. Indeed, Tambs et al. [20] report that that heritability estimates for 
liability to any anxiety disorder (including PTSD and OCD) are higher than those for 
individual anxiety subtypes. Furthermore, the common genetic influences acting across 
anxiety subtypes substantially (but not completely) overlap with the genetic factors 
associated with neuroticism [23].
The high comorbidity between addictive and anxious phenotypes may reflect shared genetic 
influences. Genetics factors contribute substantially to the phenotypic correlations between 
alcohol consumption and anxiety or depression symptoms in twins [11]. Furthermore, a 
number of studies looking at patterns of transmission in families show shared familial risk 
factors for alcohol dependence and panic disorder [5,10], consistent with the hypothesis that 
addiction and anxiety are genetically correlated traits. Nevertheless, these studies have 
tended to focus on alcohol-related phenotypes; there is less work considering whether this 
genetic overlap generalizes across addiction subtypes.
To gain insight into the neurobiology underlying the overlap between addiction and anxiety, 
it is important to both understand the extent to which genetic liabilities are common among 
traits, and identify the genetic loci that contribute to this shared liability. Linkage analysis 
within family studies can allow us to do this by identifying chromosomal regions that 
segregate in families with disease. Furthermore, linkage methods capture a diverse range of 
types of genetic effects, including common and rare variants that are also important 
contributors to the risk for psychiatric disorders [24,25]. A number of univariate genome-
wide linkage efforts have been published exploring anxiety disorders [26], and addiction 
[27–29]. While some genes implicated in this comorbidity have been linked separately to the 
risk for each disorder using candidate approaches, including neuropeptide Y [30,31] and 
GABA [32], we are unaware of any previous studies that have used linkage methods to 
investigate the comorbidity of these disorders on a genome-wide scale. Here, we employ 
bivariate linkage approaches looking at addiction and anxiety traits together, to identify 
chromosomal regions with pleiotropic influences on both traits. Bivariate linkage analysis 
provides greater statistical power to detect quantitative trait loci for correlated traits, as well 
as improved localization of the linkage signal [33], offering a powerful tool to identify 
genomic regions that jointly influence these comorbid disorders. We examine the genetic 
influences on addiction and anxiety phenotypes using a large randomly ascertained family 
sample and use both univariate and bivariate linkage analyses to identify chromosomal loci 
that underpin these phenotypes and their patterns of comorbidity.
2. Methods
2.1. Study sample
The sample consisted of 1284 Mexican-Americans from 75 extended pedigrees (containing 
2–132 subjects, mean pedigree size = 16.36, SD = 19.41) and an additional 57 genetically 
unrelated spouses. The mean age of the sample was 46.08 years (SD = 14.89, range = 18–97 
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years), and 62.7% of the sample was female. Stated pedigree relationships were confirmed 
using PREST and available autosomal markers [34].
The sample is a subset of the San Antonio Family Study cohort of individuals randomly 
ascertained with the constraints that participants must live within the San Antonio region, be 
Mexican-American in ancestry, and part of a large family (at least 6 1st degree relatives). 
Full recruitment details are available elsewhere [35,36]. All subjects provided informed 
written consent (as approved by Institutional Review Boards at the university of Texas, 
health science center San Antonio and Yale university) and the cohort have been actively 
participating in research for over 18 years.
2.2. Phenotypic assessment
The semi-structured Mini International Psychiatric Interview Plus (MINI-Plus; [37]) was 
administered to all participants, with additional questions to establish lifetime history of 
psychiatric disorders, using DSM-IV criteria [38]. Lifetime history of chronic smoking was 
defined as ever having smoked cigarettes, cigars or a pipe every day for a month or more. 
Lifetime history of alcohol dependence was assessed, as was drug dependence (here defined 
as dependence on any drugs other than tobacco or alcohol; the Supplementary materials 
includes the prompts given). Anxiety cases were defined as those patients meeting criteria 
for any of the following; panic disorder, agoraphobia, social phobia, specific phobia, OCD, 
PTSD, or generalized anxiety disorder. Prevalence by subtype is included in the 
Supplementary materials. All interviewers administering the MINI-Plus had a doctorate or 
master’s degree in a mental health field or a bachelor’s degree with at least 2 years of 
relevant experience, and high levels of diagnostic reliability were reached for anxiety and 
addiction disorders (κ > = 0.90).
2.3. Genotyping
Genotyping for approximately one million SNPs was performed using Illumina 
HumanHap550v3, HumanExon510Sv1, Human1Mv1 and Human1M-Duov3 BeadChips, 
and following the Illumina Infinitum protocol. For quality control, SNPs and samples were 
removed if < 95% of genotypes were present or if the minor allele was present in less than 
10 individuals. Allele frequencies were calculated using maximum likelihood methods to 
account for pedigree relationships [39] and SNPs were observed to be in Hardy Weinberg 
Equilibrium. SimWalk2 was used to check for Mendelian consistency and missing 
genotypes were imputed (utilizing the available pedigree information) within MERLIN [40].
For linkage analysis, a subset of 28,387 SNPs from the 1 M GWAS SNPs were selected 
using genotypes from 345 founders. SNPS were selected on each chromosome with a 
minimum spacing of 1 KB and a minor allele frequency > 5%. To limit linkage 
disequilibrium between SNPs, a limit of pairwise r2 < 0.0225 within a 100 kb sliding 
window was used. The selected subset of SNPs gave an average of 7–8 SNPs 
percentimorgan (cM). Using these 28,387 SNPs, multipoint identity-by-descent matrices 
were constructed at each centimorgan location, using a stochastic Markov Chain Monte 
Carlo procedure within LOKI [41].
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SOLAR was used for all genetic analyses [42]. This software uses maximum likelihood 
decomposition methods to model the patterns of trait covariance between family members as 
a function of genetic relationships, and so estimate the genetic and environmental 
contributions to phenotypes within a family structure. All analyses included the covariates of 
age, age2, sex and their interactions.
To identify the relative contribution of additive genetic and environmental influences for 
addiction-related and anxiety traits, univariate variance decomposition was performed, 
yielding trait heritability estimates. For each trait showing significant heritability, we 
performed genome-wide multipoint linkage analysis, to identify chromosomal loci involved 
in the trait of interest. Based on a method derived by Feingold et al. [43], it was previously 
established in this sample that a LOD score greater than 2.9 indicates a genome-wide 
significant linkage peak, whilst a LOD score over 1.67 is indicative of a suggestive peak 
(likely to occur by chance less than once per genome-wide scan) [44]. These LOD scores are 
per genome-wide scan, whilst here, we examined four correlated phenotypes (alcohol 
dependence, drug dependence, smoking and anxiety). Therefore, using the method outlined 
by Cheverud [45] to assess the genetic correlations between traits, we established that the 
effective number of traits considered was 2.61.
We then explored the genetic relationships between addiction and anxiety. First, we 
examined the covariance between each of the three addiction-related traits and anxiety, to 
obtain bivariate genetic correlations. Then, for pairs of traits where significant genetic 
correlations were observed, bivariate linkage analysis was performed [33]. To enable 
comparison with the univariate results, bivariate LOD scores were converted to a one 
degree-of-freedom equivalent (based upon the P-value for the two degrees-of-freedom test of 
linkage to both traits versus linkage to neither). In order to assess whether bivariate linkage 
signals were truly bivariate in nature, nested models were compared to test whether the 
model could be explained in the absence of any shared genetic effect; that is where co-
occurrence of linkage peaks in the two traits occurred by chance [46]. A confidence interval 
of maximum LOD score −1 was defined surrounding each significant linkage peak.
To follow up any significant linkage signals, we extracted SNPs that were located within 
each significant peak from the full 1 M GWAS SNPs. Using the measured genotype 
association (mga) method, where models include the fixed effect of the SNP and random 
effects of local and polygenic heritability, individual SNPs were associated traits of interest. 
An additive genetic model was assumed, and the first four principal components of the 
GWAS data were included as covariates to account for population and admixture 
substructure within pedigrees [47]. To test for significance, a likelihood ratio test was 
employed, comparing models where the genotype parameter is allowed to vary freely or is 
fixed to zero. Given linkage disequilibrium, the pairwise correlations between SNPs were 
used to calculate the effective number of independent tests within each region [48], for an 
appropriate multiple-testing correction.
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The prevalence and heritability of each trait is shown in Table 1. As expected, for addiction 
phenotypes, there are fewer female than male cases, but the majority of anxiety cases are 
female. When calculating the heritability of each trait, sex was a significant covariate for all 
phenotypes (details are given in the Supplementary materials).
Univariate genome-wide linkage scans were performed for each of the four phenotypes 
under consideration. Significant linkage peaks were observed for drug dependence on 
chromosome 14 at 41cM (LOD score = 3.322) and for anxiety on chromosome 12 at 164cM 
(LOD = 2.918). For alcohol dependence and smoking, genome-wide significance was not 
reached. The maximum linkage for alcohol dependence was on chromosome 16 at 54cM 
(LOD score = 2.752) and for smoking on chromosome 4 at 80cM (LOD score = 2.735). The 
maximum peak for every trait is shown in Fig. 1. The Supplementary materials includes 
details on the genes located within each of these peaks, as well as plots of genome-wide 
linkage results for all four traits. The linkage signal for anxiety on chromosome 12 
encompasses TMEM132D, which has previously been associated with anxiety-related traits 
[49–53]. Each of the univariate linkage signals is specific to the trait of interest; LOD scores 
are below 0.7 for all other traits in each of the identified chromosomal loci.
3.2. Bivariate analyses
The patterns of comorbidity between addiction subtypes and anxiety are shown in Table 2 
(comorbidity rates amongst the addiction subtypes are in the Supplementary materials). 
Patterns of shared genetic underpinnings are evident (Table 3) with significant positive 
genetic correlations observed between anxiety and each of the addiction traits.
Bivariate linkage scans were performed for anxiety with each of the addiction traits. 
Evidence of pleiotropic genomic regions were observed in two cases. For alcohol 
dependence and anxiety, a significant bivariate peak was observed on chromosome 9 (at 
133cM, LOD = 3.054). At this location, the univariate linkage analyses gave a LOD = 2.562 
for alcohol dependence and LOD = 1.673 for anxiety. Using nested models to compare 
coincident with pleiotropic models, this peak was observed to be pleiotropic (χ2[1] = 11.38, 
p = 3.71 × 10−4). A second significant bivariate linkage peak was observed for drug 
dependence and anxiety on chromosome 18 at 29 cm (LOD = 3.425, pleiotropy test χ2[l] = 
16.02, p = 3.14 × 10−5). The univariate linkage signals at this locus were LOD = 1.098 for 
drug dependence and LOD = 1.887 for anxiety. No significant bivariate linkage was 
observed for anxiety and smoking. The significant bivariate linkage peaks are shown in Fig. 
2. Genes located within these peaks and plots of the full genome-wide linkage results are in 
the Supplementary materials.
3.3. Association analysis of significant linkage peaks
We performed mga analysis using all of the available SNPs underneath each of the four 
significant linkage peaks identified. No SNPs reached peak-wide significance, for any of the 
four regions considered, although the most significant SNP for anxiety (rs10744424) is 
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within TMEM132D. Details of the best performing SNPs for each region are given in Table 
4.
4. Discussion
4.1. Summary of findings
We have demonstrated that shared genetic influences play an important role in the high rates 
of comorbidity between anxiety and addiction (examining alcohol dependence, drug 
dependence and chronic smoking in turn). We observed genetic correlations between 0.550–
0.655 within a Mexican-American extended pedigree sample. This is consistent with 
previous findings for anxiety and alcohol dependence [5,10,11] and our genetic correlation 
estimates are also similar to those observed when considering addiction in relation to major 
depression [54,55].
Having established a common genetic etiology, we used genome-wide linkage analyses to 
identify specific and pleiotropic quantitative trait loci for these phenotypes. Genome-wide 
significant univariate linkage signals were observed for drug dependence at 14q13.2–q21.2 
and for anxiety at 12q24.32–q24.33. Genomewide significant bivariate linkage peaks were 
observed for alcohol dependence-anxiety at 9q33.1–q33.2 and for drug dependence-anxiety 
at 18p11.23–p11.22. For each of the phenotypes considered here, the identified quantitative 
trait loci were phenotype specific; LOD scores were low (< 0.7) in the univariate linkage 
scans of the other traits, despite the high genetic correlations among traits. It suggests that 
these loci are phenotype-specific, without pleiotropic effects on the other traits studied. 
However, given the limited power to detect loci of small effect, it is also possible that the 
loci were detected only through the phenotype on which they exert the largest effect and 
potential pleiotropic effects on the other phenotypes cannot be excluded. We used mga 
analyses to try to localize these linkage signals, using available SNP data. We were unable to 
identify any peak-wide significant SNP associations; this may be as we were only able to 
examine common SNPs or possibly due to sample size limitations.
4.2. Previously implicated genomic locations
The significant linkage signals identified in this analysis show some interesting convergence 
with previous findings in psychiatric genetics. First, in the univariate analysis of anxiety, we 
observed a significant linkage peak on chromosome 12q24.32–q24.33. While this peak only 
just reaches the threshold for genome-wide significance, it is of particular interest given that 
TMEM132D (transmembrane protein 132D) lies within this region. This gene was first 
implicated through GWAS investigation of panic disorder, with mouse model evidence 
supporting an involvement in anxious behavior [49]. Since then, both common and rare 
variants within the gene have been associated with anxiety disorders [50–52] and links have 
also been observed between variants in this gene, amygdala volume and anxiety traits in 
healthy controls [53]. Using association analysis in this region, the best performing SNP in 
our sample is rs10744424 (intronic within TMEM132D), although it does not reach 
significance when correcting for all SNPs available in the 2.66MB linkage region. 
Therefore, the identification here of a linkage peak for anxiety in the same genomic region 
as previous research is consistent with the role of the gene in liability to anxiety disorders, 
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but as we are unable to more specifically localize the signal within this peak, our findings 
are not conclusive.
Second, we localize a bivariate linkage signal between alcohol dependence and anxiety at 
9q33.1–q33.2. Previous work has linked rare CNVs within 9q33 to a number of traits, 
including neurodevelopmental delays and psychiatric disorders including anxiety [56]. There 
has also been some evidence of linkage in this region with addiction traits; in a study of 
alcohol-related traits a suggestive linkage peak was observed in the same location [57] and 
in a 2008 review of genome-wide linkage studies in smoking, this region had been 
implicated in four independent samples [58], although this signal was not observed in a later 
meta-analysis [27] and the signal has not been localized to a specific gene. Therefore, there 
is some tentative evidence that this genomic region may be linked to liability to a number of 
psychiatric traits.
The remaining linkage peaks (for drug dependence on chromosome 14 and for drug 
dependence-anxiety on chromosome 18) identified in this study appear to be in regions that 
have not previously been highlighted in addiction genetics. Generally, for illicit drugs, the 
genetic loci involved are not well established, which may in part be due to the difficulties in 
obtaining sufficiently large samples of drug dependent individuals for adequately powered 
genetic studies. Indeed, the drug dependent group contains individuals that are addicted to a 
range of different illicit drugs (such as cannabis, cocaine or tranquilizers). By grouping these 
individuals into a single category, we are able to increase statistical power to detect genetic 
effects that are common among these illicit drugs and detect both univariate and pleiotropic 
linkage signals, although drug-specific signals may be obscured.
It is of note that we did not observe genome-wide linkage signals within either univariate or 
bivariate models for smoking within this sample, using an “ever vs never” categorization to 
assess initiation of chronic smoking. This is despite significant trait heritability (h2 = 0.554) 
and genetic correlation with anxiety (ρg = 0.550). There has been greater success in the 
literature using smoking quantity or nicotine dependence phenotypes, which are genetically 
overlapping but not identical to smoking initiation [59]. However, these measures are 
unavailable in this sample. In a comprehensive meta-analysis of linkage studies looking at 
3404 families, genome-wide significance was only observed with the phenotype of 
“maximum number of cigarettes per day”, on chromosome 20q13.12–13.32 [27]. 
Interestingly, in this metaanalysis, they failed to find evidence on linkage on chromosome 
15q25, the location of the nicotinic acetylcholine receptor gene cluster which is a well-
established hit for the phenotype of “cigarettes per day” from genome-wide association 
approaches [60].
4.3. Implications of findings
As a complex trait, addiction is likely to be highly polygenic, with both general and 
substance-specific components; the genetic loci identified to date only account for a small 
proportion of the variance in liability to addiction. Similarly, the genetic influences on 
anxiety traits remain poorly understood. By considering the relationships between addiction 
and anxiety, we aimed to reveal details of the genetic architecture underlying these comorbid 
traits. By demonstrating genetic correlations between addiction subtypes and anxiety, we 
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have shown that shared genetic etiology plays an important role in the high rates of 
comorbidity, although this does not exclude the existence of causal pathways between the 
two types of disorder. It still remains that addiction could manifest as a result of anxiety 
symptoms, or indeed vice versa. We suggest that a single generality is unlikely, 
heterogeneity between individuals and a pattern of multiple interacting pathways fits the 
diverse clinical picture more accurately. However, to begin to understand the biological 
pathways responsible for the shared genetic etiology of these two disorders, we must 
identify the specific genes involved.
Leveraging the increased statistical power of bivariate linkage analyses to identify the 
regions of the genome involved in this shared genetic etiology [33], we have highlighted 
potential pleiotropic regions of the genome, implicating both previously identified and novel 
chromosomal loci that may contribute risk for each these diagnoses. These regions point to 
candidates for further research into these disorders, and offer a potential starting point to 
begin to unpick the underlying neurobiology for each diagnosis and understand how they 
might be interconnected.
4.4. Characteristics of the sample
Our study examines a Mexican-American sample. Within the USA, it has been shown that 
the prevalence of addiction and psychiatric disorders in amongst Hispanics is generally 
lower than amongst non-Hispanic Caucasians; this is also true for black and Asians 
minorities [7,61]. However, there is variation within ethnic minority subgroups, according to 
interacting factors including country of origin, level of discrimination and acculturation [62–
65]. Relating the prevalence of disorder within the sample to US national averages, we find 
that addiction phenotypes are more common in this sample, however, rates of anxiety are 
comparable to those reported in large epidemiological surveys [7,61].
In defining anxiety in this sample, we grouped all anxiety diagnoses along with PTSD and 
OCD together into a single category. This approach of grouping rather than splitting was 
taken for two reasons; first due to low numbers of cases for some diagnoses. Second, whilst 
this grouping does not capture known anxiety disorder-specific genetic influences, previous 
work shows that when all anxiety disorders (including PTSD and OCD) are considered, a 
common pathway model best describes the relationship between disorders, with most of the 
genetic effects being shared across disorders [20]. Additional epidemiological [66] and twin 
[21] research supports this approach. Whilst we relied upon DSM-IV criteria [38] to classify 
alcohol dependence, substance dependence and anxiety disorders, we note that in DSM-V 
[67] (published after the collection of this data), OCD and PTSD have been moved from the 
Anxiety Disorders chapter (to adjacent chapters of Obsessive-Compulsive and Related 
Disorders and Trauma and Stressor-Related Disorders) and changes have been made to 
criteria defining substance use disorders.
It is known that patients recruited into a study from a treatment setting often differ from the 
general population of affected individuals, particularly in terms of symptom severity and 
patterns of comorbidity [68]. By using a randomly ascertained extended pedigree sample, we 
have side-stepped these potential biases. Additionally, the extended pedigree design that we 
employ here offers increased power to detect quantitative trait loci over smaller family units 
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in most circumstances [69], and while family studies typically do not directly estimate the 
influence of environments shared by family members (as twin studies do), the inflation of 
heritability estimates by these shared environmental influences are much less likely in 
multigenerational families such as those included in this sample [70].
Given the contrasting prevalence by sex of addiction and anxiety, paired with overlapping 
genetic liability, the manifestation of symptoms associated with this shared vulnerability 
may differ by gender. It would be of interest to model genetic liability to these comorbidity 
disorders in a sex-specific manner. However, this sample is not well suited to tackle the 
issue, as sex-specific analyses would require breaking up the extended pedigree structure, 
resulting in a substantial loss of statistical power and further, only autosomal chromosomes 
are considered in this analysis.
5. Conclusions
In this study, we observe a number of significant quantitative trait loci that underlie the 
genetic overlap of the addiction subtypes of alcohol dependence, drug dependence and 
smoking with anxiety, within a randomly ascertained sample. The regions we identify show 
some convergence with previous literature, but also highlight a number of novel genomic 
loci involved in the comorbidity of these psychiatric traits.
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Signficant univariate linkage signals. Alcohol dependence (Chr 16LOD = 2.752 at 54cM); 
drug dependence (Chr 14LOD = 3.322 at 41cM); smoking (Chr 4 LOD = 2.735 at 80cM); 
anxiety (Chr 12 LOD = 2.918 at 164cM).
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Significant bivariate linkage signals. Alcohol dependence and anxiety (Chr 9 at 133cM, 
bivariate LOD = 3.054); drug dependence and anxiety (Chr 18 at 29cM, bivariate LOD = 
3.425). Bivariate linkage shown in grey, overlaid on univariate signals.
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Table 2
Addiction cases with comorbid anxiety.
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Table 3
Phenotypic and genetic correlations between addiction traits and anxiety.
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Table 4
Best performing snps in association analysis. No snps pass peak-wide significance.
Drug dependence Anxiety Alcohol dependence/anxiety Drug dependence/anxiety
Chromosome 14 12 9 18
Size of linkage peak region 
(Mb)
8.46 2.66 4.98 1.20
No. of SNPs in peak 2728 1443 1643 552
Effective no. of SNPs in peak 1364.97 952.619 898.131 337.16
Peak-wide P-value threshold 3.76E-05 5.38E-05 5.71E-05 1.52E-04
Min P-value observed 2.62E-04 7.80E-05 1.30E-04 2.27E-03
Best SNP rs17113722 rs10744424 rs10117151 rs11661395
Alleles C/T A/G A/C C/T
SNP MAF 0.052 0.117 0.433 0.478
Allele frequency in 1000 
genomes MXL population
0.070 0.133 0.469 0.523
Allele frequency in 1000 
genomes EUR population
0.082 0.156 0.625 0.416
Allele frequency in Alfred Pima 
Bajo population
0.020 0.000 0.120 Not available
Nearest gene LRFN5 (nearest) TMEM132D (intronic) ASTN2 (nearest) RAB12 (nearest)
Eur Psychiatry. Author manuscript; available in PMC 2017 June 26.
